logo

Scynexis, Inc. (SCYX)



Trade SCYX now with
  Date
  Headline
11/12/2019 8:37:52 AM SCYNEXIS Q3 Net Loss $7.9 Mln Vs. Net Income $0.4 Mln Last Year
11/7/2019 8:13:16 AM SCYNEXIS Reports Results From First Phase 3 Registration Study Of Oral Ibrexafungerp In Vulvovaginal Candidiasis
9/18/2019 8:35:23 AM SCYNEXIS Completes Last-Patient In First Phase 3 Study Of Oral Ibrexafungerp For Treatment Of VVC
7/24/2019 9:02:27 AM SCYNEXIS Announces SPA Deal With FDA For Phase 3 Study Evaluating Oral Ibrexafungerp For Prevention Of Recurrent VVC
6/14/2019 8:32:20 AM SCYNEXIS Appoints Nkechi Azie As VP Of Clinical Development
5/30/2019 8:33:17 AM SCYNEXIS Completes Chronic Nonclinical Toxicology Studies Supporting Long-Term Administration Of Ibrexafungerp
5/6/2019 8:32:36 AM SCYNEXIS Presents Data Further Supporting A Future NDA Submission Of Oral Ibrexafungerp For Vulvovaginal Candidiasis
4/3/2019 8:34:03 AM SCYNEXIS Reports Data Demonstrating Potential Use Of Ibrexafungerp As Agent To Address Multiple Serious Fungal Infection
2/28/2019 8:33:12 AM SCYNEXIS To Present Pre-clinical Data Supporting Prophylactic Use Of Ibrexafungerp At Superbugs And Superdrugs 2019
1/22/2019 8:47:24 AM SCYNEXIS Appointms Armando Anido To Its Board
11/13/2018 9:21:38 AM SCYNEXIS Q3 Net Income $0.4 Mln Or $0.01/shr Vs Net Loss Of $8.4 Mln Or $0.31/shr Prior Year
10/23/2018 9:19:43 AM SCYNEXIS Completes End-of-Phase 2 Meeting With FDA For Lead Product Candidate, Ibrexafungerp
10/15/2018 9:28:27 AM SCYNEXIS :First Patient Dosed In Phase 3 Open-label Study Evaluating Oral Ibrexafungerp In Candida Auris Infections
  
 
>